Recent advances in the treatment of C. difficile using biotherapeutic agents

References

• Vindigni SM, Broussard EK, Surawicz CM. Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond. Expert Rev Gastroenterol Hepatol. 2013;7(7):615–628. doi:10.1586/17474124.2013.83250124070153
   PubMed Web of Science ®Google Scholar
• Tsutsumi LS, Owusu YB, Hurdle JG, Sun D. Progress in the discovery of treatments for C. difficile infection: a clinical and medicinal chemistry review. Curr Top Med Chem. 2014;14(1):152–175.24236721
   PubMed Web of Science ®Google Scholar
• Kim PK, Huh HC, Cohen HW, et al. Intracolonic vancomycin for severe Clostridium difficile colitis. Surg Infect (Larchmt). 2013;14(6):532–539. doi:10.1089/sur.2012.15823560732
   PubMed Web of Science ®Google Scholar
• Mulcahy-O’Grady H, Workentine ML, Challenge T. Potential of metagenomics in the clinic. Front Immunol. 2016;7:29. doi:10.3389/fimmu.2016.0002926870044
   PubMed Web of Science ®Google Scholar
• Khan FY, Elzouki AN. Clostridium difficile infection: a review of the literature. Asian Pac J Trop Med. 2014;7s1:S6–S13. doi:10.1016/S1995-7645(14)60197-825312190
   PubMed Web of Science ®Google Scholar
• McCarville JL, Caminero A, Verdu EF. Novel perspectives on therapeutic modulation of the gut microbiota. Therap Adv Gastroenterol. 2016;9(4):580–593. doi:10.1177/1756283X16637819
   Web of Science ®Google Scholar
• Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27–37. doi:10.2147/IJGM.S9828026955289
   PubMed Web of Science ®Google Scholar
• Di Bella S, Ascenzi P, Siarakas S, Petrosillo N, Di Masi A. Clostridium difficile Toxins A and B: insights into pathogenic properties and extraintestinal effects. Toxins. 2016;8(5):134. doi:10.3390/toxins8050134
   PubMed Web of Science ®Google Scholar
• Sofia MA, Rubin DT. The impact of therapeutic antibodies on the management of digestive diseases: history, current practice, and future directions. Dig Dis Sci. 2017;62(4):833–842. doi:10.1007/s10620-017-4479-028197743
   PubMed Web of Science ®Google Scholar
• Baines SD, Wilcox MH. Antimicrobial resistance and reduced susceptibility in Clostridium difficile: potential consequences for induction, treatment, and recurrence of C. difficile infection. Antibiotics. 2015;4(3):267–298. doi:10.3390/antibiotics403026727025625
   PubMedGoogle Scholar
• Ofosu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol. 2016;29(2):147–154. doi:10.20524/aog.2016.000627065726
   PubMed Web of Science ®Google Scholar
• von Müller L. Aktuelles zu Clostridium-difficile-infektionen. Dtsch Med Wochenschr. 2016;141(16):1144–1147. doi:10.1055/s-0042-10744327509341
   PubMed Web of Science ®Google Scholar
• Lübbert C, John E, von Müller L. Clostridium Difficile infection: guideline-based diagnosis and treatment. Dtsch Arztebl Int. 2014;111(43):723–731. doi:10.3238/arztebl.2014.072325404529
   PubMed Web of Science ®Google Scholar
• Dial S, Kezouh A, Dascal A, Barkun A, Suissa S. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ. 2008;179(8):767–772. doi:10.1503/cmaj.07181218838451
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother. 2008;62(2):388–396. doi:10.1093/jac/dkn16318434341
   PubMed Web of Science ®Google Scholar
• Tenover FC, Tickler IA, Persing DH. Antimicrobial-resistant strains of Clostridium difficile from North America. Antimicrob Agents Chemother. 2012;56(6):2929–2932. doi:10.1128/AAC.00220-1222411613
   PubMed Web of Science ®Google Scholar
• Fuzi M. Dissimilar fitness associated with resistance to fluoroquinolones influences clonal dynamics of various multiresistant bacteria. Front Microbiol. 2016;7:1017. doi:10.3389/fmicb.2016.0101727458434
   PubMed Web of Science ®Google Scholar
• Abdulgader SM, Shittu AO, Nicol MP, Kaba M. Molecular epidemiology of Methicillin-resistant Staphylococcus aureus in Africa: a systematic review. Front Microbiol. 2015;6:348. doi:10.3389/fmicb.2015.0034825983721
   PubMed Web of Science ®Google Scholar
• Wasels F, Kuehne SA, Cartman ST, et al. Fluoroquinolone resistance does not impose a cost on the fitness of Clostridium difficile in vitro. Antimicrob Agents Chemother. 2015;59(3):1794–1796. doi:10.1128/AAC.04503-1425534738
   PubMed Web of Science ®Google Scholar
• Valiente E, Cairns MD, Wren BW. The Clostridium difficile PCR ribotype 027 lineage: a pathogen on the move. Clin Microbiol Infect. 2014;20(5):396–404. doi:10.1111/1469-0691.1261924621128
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee Y, Lee K, Riley TV, Kim H. The changes of PCR ribotype and antimicrobial resistance of Clostridium difficile in a tertiary care hospital over 10 years. J Med Microbiol. 2014;63(Pt 6):819–823. doi:10.1099/jmm.0.072082-024696516
   PubMed Web of Science ®Google Scholar
• Kouzegaran S, Ganjifard M, Tanha AS. Detection, ribotyping and antimicrobial resistance properties of Clostridium difficile strains isolated from the Cases of Diarrhea. Mater Sociomed. 2016;28(5):324–328. doi:10.5455/msm.2016.28.324-32827999477
   PubMedGoogle Scholar
• Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014;7:63–72. doi:10.2147/IDR.S4678024669194
   PubMed Web of Science ®Google Scholar
• Lambert PJ, Dyck M, Thompson LH, Hammond GW. Population-based surveillance of Clostridium difficile infection in Manitoba, Canada, by using interim surveillance definitions. Infect Control Hosp Epidemiol. 2009;30(10):945–951. doi:10.1086/60571919732008
   PubMed Web of Science ®Google Scholar
• Bloomfield LE, Riley TV. Epidemiology and risk factors for community-associated Clostridium difficile infection: a narrative review. Infect Dis Ther. 2016;5(3):231–251. doi:10.1007/s40121-016-0117-y27370914
   PubMedGoogle Scholar
• Martinez FJ, Leffler DA, Kelly CP. Clostridium difficile outbreaks: prevention and treatment strategies. Risk Manag Healthc Policy. 2012;5:55–64. doi:10.2147/RMHP.S1305322826646
   PubMedGoogle Scholar
• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–834. doi:10.1056/NEJMoa140891325714160
   PubMed Web of Science ®Google Scholar
• Ozaki E, Kato H, Kita H, et al. Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. J Med Microbiol. 2004;53(Pt 2):167–172. doi:10.1099/jmm.0.05376-014729940
   PubMed Web of Science ®Google Scholar
• Spigaglia P. Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Ther Adv Infect Dis. 2016;3(1):23–42. doi:10.1177/204993611562289126862400
   PubMed Web of Science ®Google Scholar
• Chaparro-Rojas F, Mullane KM. Emerging therapies for Clostridium difficile infection - focus on fidaxomicin. Infect Drug Resist. 2013;6:41–53. doi:10.2147/IDR.S2443423843696
   PubMedGoogle Scholar
• Chandrasekaran R, Lacy DB. The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev. 2017;41(6):723–750. doi:10.1093/femsre/fux04829048477
   PubMed Web of Science ®Google Scholar
• Aktories K, Papatheodorou P, Schwan C. Binary Clostridium difficile toxin (CDT) - A virulence factor disturbing the cytoskeleton. Anaerobe. 2018. doi:10.1016/j.anaerobe.2018.03.001
   Web of Science ®Google Scholar
• Samarkos M, Mastrogianni E, Kampouropoulou O. The role of gut microbiota in Clostridium difficile infection. Eur J Intern Med. 2018;50:28–32. doi:10.1016/j.ejim.2018.02.00629428498
   PubMed Web of Science ®Google Scholar
• Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012;55 Suppl 2:S93–S103. doi:10.1093/cid/cis49922752871
   PubMed Web of Science ®Google Scholar
• Wolfe C, Pagano P, Pillar CM, Shinabarger DL, Boulos RA. Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin, and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution. Diagn Microbiol Infect Dis. 2018;92(3):250–252. doi:10.1016/j.diagmicrobio.2018.06.00230042035
   PubMed Web of Science ®Google Scholar
• Cornely OA, Watt M, McCrea C, Goldenberg SD, De Nigris E. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged >/=60 years (EXTEND): analysis of cost-effectiveness. J Antimicrob Chemother. 2018;73(9):2529–2539. doi:10.1093/jac/dky18429800295
   PubMed Web of Science ®Google Scholar
• Baro E, Galperine T, Denies F, et al. Cost-effectiveness analysis of five competing strategies for the management of multiple recurrent community-onset Clostridium difficile infection in France. PLoS One. 2017;12(1):e0170258. doi:10.1371/journal.pone.017025828103289
   PubMed Web of Science ®Google Scholar
• Jiang M, N-H L, Ip M, You JHS. Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe Clostridium difficile infection. PLoS One. 2018;13(7):e0201539. doi:10.1371/journal.pone.020153930048534
   PubMed Web of Science ®Google Scholar
• Le P, Nghiem VT, Mullen PD, Deshpande A. Cost-effectiveness of competing treatment strategies for Clostridium difficile infection: a systematic review. Infect Control Hosp Epidemiol. 2018;39(4):412–424. doi:10.1017/ice.2017.30329463339
   PubMed Web of Science ®Google Scholar
• Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med. 2006;73(2):187–197.16478043
   PubMed Web of Science ®Google Scholar
• Dostal A, Lacroix C, Bircher L, et al. Iron modulates butyrate production by a child gut microbiota In Vitro. mBio. 2015;6:6. doi:10.1128/mBio.01453-15
   Web of Science ®Google Scholar
• Chilton CH, Crowther GS, Spiewak K, et al. Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection. J Antimicrob Chemother. 2016;71(4):975–985. doi:10.1093/jac/dkv45226759363
   PubMed Web of Science ®Google Scholar
• Zanella Terrier MC, Simonet ML, Bichard P, Frossard JL. Recurrent Clostridium difficile infections: the importance of the intestinal microbiota. World J Gastroenterol. 2014;20(23):7416–7423. doi:10.3748/wjg.v20.i23.741624966611
   PubMed Web of Science ®Google Scholar
• Perez-Cobas AE, Moya A, Gosalbes MJ, Latorre A. Colonization resistance of the gut microbiota against Clostridium difficile. Antibiotics (Basel). 2015;4(3):337–357. doi:10.3390/antibiotics403033727025628
   PubMedGoogle Scholar
• Wehrhahn MC, Keighley C, Kurtovic J, et al. A series of three cases of severe Clostridium difficile infection in Australia associated with a binary toxin producing clade 2 ribotype 251 strain. Anaerobe. 2018;55:117–123. doi:10.1016/j.anaerobe.2018.11.009.
   Web of Science ®Google Scholar
• King AM, Mackin KE, Lyras D. Emergence of toxin A-negative, toxin B-positive Clostridium difficile strains: epidemiological and clinical considerations. Future Microbiol. 2015;10(1):1–4. doi:10.2217/fmb.14.11525598331
   PubMed Web of Science ®Google Scholar
• Chaves-Olarte E, Freer E, Parra A, Guzman-Verri C, Moreno E, Thelestam M. R-Ras glucosylation and transient RhoA activation determine the cytopathic effect produced by toxin B variants from toxin A-negative strains of Clostridium difficile. J Biol Chem. 2003;278(10):7956–7963. doi:10.1074/jbc.M20924420012496290
   PubMed Web of Science ®Google Scholar
• Stewart DB, Berg A, Hegarty J. Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key. J Gastrointest Surg. 2013;17(1):118–124;discussion p.124–115. doi:10.1007/s11605-012-2056-6
   Web of Science ®Google Scholar
• Hutton ML, Mackin KE, Chakravorty A, Lyras D. Small animal models for the study of Clostridium difficile disease pathogenesis. FEMS Microbiol Lett. 2014;352(2):140–149. doi:10.1111/1574-6968.1236724372713
   PubMed Web of Science ®Google Scholar
• Cowardin CA, Buonomo EL, Saleh MM, et al. The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia. Nat Microbiol. 2016;1(8):16108. doi:10.1038/nmicrobiol.2016.10827573114
   PubMed Web of Science ®Google Scholar
• Darkoh C, DuPont HL, Norris SJ, Kaplan HB. Toxin synthesis by Clostridium difficile is regulated through quorum signaling. MBio. 2015;6(2):e02569. doi:10.1128/mBio.02569-1425714717
   PubMed Web of Science ®Google Scholar
• Lyon SA, Hutton ML, Rood JI, Cheung JK, Lyras D. CdtR regulates TcdA and TcdB production in Clostridium difficile. PLoS Pathog. 2016;12(7):e1005758. doi:10.1371/journal.ppat.100575827414650
   PubMed Web of Science ®Google Scholar
• Culligan EP, Hill C, Sleator RD. Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog. 2009;1(1):19. doi:10.1186/1757-4749-1-1919930635
   PubMed Web of Science ®Google Scholar
• Wong A, Ngu DYS, Dan LA, Ooi A, Lim RLH. Detection of antibiotic resistance in probiotics of dietary supplements. Nutr J. 2015;14(1):95. doi:10.1186/s12937-015-0084-226370532
   PubMed Web of Science ®Google Scholar
• Zheng M, Zhang R, Tian X, Zhou X, Pan X, Wong A. Assessing the risk of probiotic dietary supplements in the context of antibiotic resistance. Front Microbiol. 2017;8:908–908. doi:10.3389/fmicb.2017.0090828579981
   PubMed Web of Science ®Google Scholar
• Maziade PJ, Pereira P, Goldstein EJ. A decade of experience in primary prevention of Clostridium difficile infection at a community hospital using the probiotic combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). Clin Infect Dis. 2015;60 Suppl 2:S144–147. doi:10.1093/cid/civ17825922400
   PubMed Web of Science ®Google Scholar
• More MI, Vandenplas Y. Saccharomyces boulardii CNCM I-745 improves intestinal enzyme function: a trophic effects review. Clin Med Insights Gastroenterol. 2018;11:1179552217752679. doi:10.1177/117955221775267929449779
   PubMedGoogle Scholar
• Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31(4):1012–1017. doi:10.1086/31813011049785
   PubMed Web of Science ®Google Scholar
• Pozzoni P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2012;107(6):922–931. doi:10.1038/ajg.2012.5622472744
   PubMed Web of Science ®Google Scholar
• Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis. 2003;35(6–7):365–367. doi:10.1080/0036554031001098512953945
   PubMed Web of Science ®Google Scholar
• Gueimonde M, Sanchez B, GdLR-G C, Margolles A. Antibiotic resistance in probiotic bacteria. Front Microbiol. 2013;4:202. doi:10.3389/fmicb.2013.0007723882264
   PubMed Web of Science ®Google Scholar
• Cameron D, Hock QS, Kadim M, et al. Probiotics for gastrointestinal disorders: proposed recommendations for children of the Asia-Pacific region. World J Gastroenterol. 2017;23(45):7952–7964. doi:10.3748/wjg.v23.i45.795229259371
   PubMed Web of Science ®Google Scholar
• Julliard W, De Wolfe TJ, Fechner JH, Safdar N, Agni R, Mezrich JD. Amelioration of Clostridium difficile infection in mice by dietary supplementation with indole-3-carbinol. Ann Surg. 2017;265(6):1183–1191. doi:10.1097/SLA.000000000000183027280500
   PubMed Web of Science ®Google Scholar
• Hryckowian AJ, Pruss KM, Sonnenburg JL. The emerging metabolic view of Clostridium difficile pathogenesis. Curr Opin Microbiol. 2017;35:42–47. doi:10.1016/j.mib.2016.11.00627997854
   PubMed Web of Science ®Google Scholar
• Dolan KT, Chang EB. Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases. Mol Nutr Food Res. 2017;61(1). doi:10.1002/mnfr.201600129
   PubMed Web of Science ®Google Scholar
• Kelly CP, Kyne L. The host immune response to Clostridium difficile. J Med Microbiol. 2011;60(Pt 8):1070–1079. doi:10.1099/jmm.0.030015-021415200
   PubMed Web of Science ®Google Scholar
• Solomon K. The host immune response to Clostridium difficile infection. Ther Adv Infect Dis. 2013;1(1):19–35. doi:10.1177/204993611247217325165542
   PubMedGoogle Scholar
• Mathur H, Rea MC, Cotter PD, Ross RP, Hill C. The potential for emerging therapeutic options for Clostridium difficile infection. Gut Microbes. 2014;5(6):696–710. doi:10.4161/19490976.2014.98376825564777
   PubMed Web of Science ®Google Scholar
• Simon M, Chervin S, Brown S, et al. Polyclonal Antibody Therapies for Clostridium difficile Infection. Antibodies. 2014;3:272–288. doi:10.3390/antib3040272
   Google Scholar
• Hurez V, Kazatchkine MD, Vassilev T, et al. Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood. 1997;90(10):4004–4013.9354669
   PubMed Web of Science ®Google Scholar
• Humphreys DP, Wilcox MH. Antibodies for treatment of Clostridium difficile infection. Clin Vaccine Immunol. 2014;21(7):913–923. doi:10.1128/CVI.00116-1424789799
   PubMedGoogle Scholar
• Torres JF, Lyerly DM, Hill JE, Monath TP. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun. 1995;63(12):4619–4627.7591115
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Marbury TC, Foglia G, Warny M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine. 2012;30(13):2245–2249. doi:10.1016/j.vaccine.2012.01.06522306375
   PubMed Web of Science ®Google Scholar
• Feher C, Mensa J. A comparison of current guidelines of five international societies on Clostridium difficile infection management. Infect Dis Ther. 2016;5(3):207–230. doi:10.1007/s40121-016-0122-127470257
   PubMed Web of Science ®Google Scholar
• Feher C, Soriano A, Mensa J. A review of experimental and off-label therapies for Clostridium difficile infection. Infect Dis Ther. 2017;6(1):1–35. doi:10.1007/s40121-016-0140-z27910000
   PubMed Web of Science ®Google Scholar
• Broecker F, Hanske J, Martin CE, et al. Multivalent display of minimal Clostridium difficile glycan epitopes mimics antigenic properties of larger glycans. Nat Commun. 2016;7:11224. doi:10.1038/ncomms1122427091615
   PubMed Web of Science ®Google Scholar
• Kirk JA, Banerji O, Fagan RP. Characteristics of the Clostridium difficile cell envelope and its importance in therapeutics. Microb Biotechnol. 2017;10(1):76–90. doi:10.1111/1751-7915.1237227311697
   PubMed Web of Science ®Google Scholar
• Hussack G, Tanha J. An update on antibody-based immunotherapies for Clostridium difficile infection. Clin Exp Gastroenterol. 2016;9:209–224. doi:10.2147/CEG.S8401727536153
   PubMedGoogle Scholar
• Sun X, Hirota SA. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol Immunol. 2015;63(2):193–202. doi:10.1016/j.molimm.2014.09.00525242213
   PubMed Web of Science ®Google Scholar
• Karczewski J, Zorman J, Wang S, et al. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection. Vaccine. 2014;32(24):2812–2818. doi:10.1016/j.vaccine.2014.02.02624662701
   PubMed Web of Science ®Google Scholar
• Spencer J, Leuzzi R, Buckley A, et al. Vaccination against Clostridium difficile using toxin fragments: observations and analysis in animal models. Gut Microbes. 2014;5(2):225–232. doi:10.4161/gmic.2771224637800
   PubMed Web of Science ®Google Scholar
• Leuzzi R, Spencer J, Buckley A, et al. Protective efficacy induced by recombinant Clostridium difficile toxin fragments. Infect Immun. 2013;81(8):2851–2860. doi:10.1128/IAI.01341-1223716610
   PubMed Web of Science ®Google Scholar
• Wang H, Sun X, Zhang Y, et al. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun. 2012;80(8):2678–2688. doi:10.1128/IAI.00215-1222615245
   PubMed Web of Science ®Google Scholar
• Wang YK, Yan YX, Kim HB, et al. A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters. Hum Vaccin Immunother. 2015;11(9):2215–2222. doi:10.1080/21645515.2015.105235226036797
   PubMed Web of Science ®Google Scholar
• Secore S, Wang S, Doughtry J, et al. Development of a novel vaccine containing binary toxin for the prevention of Clostridium difficile disease with enhanced efficacy against NAP1 strains. PLoS One. 2017;12(1):e0170640. doi:10.1371/journal.pone.017064028125650
   PubMed Web of Science ®Google Scholar
• Leuzzi R, Adamo R, Scarselli M. Vaccines against Clostridium difficile. Hum Vaccin Immunother. 2014;10(6):1466–1477. doi:10.4161/hv.2842824637887
   PubMed Web of Science ®Google Scholar
• Yang Z, Ramsey J, Hamza T, et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2015;83(2):822–831. doi:10.1128/IAI.02897-1425486992
   PubMed Web of Science ®Google Scholar
• Anosova NG, Cole LE, Li L, et al. A combination of three fully human toxin A- and toxin B-specific monoclonal antibodies protects against challenge with highly virulent epidemic strains of Clostridium difficile in the hamster model. Clin Vaccine Immunol. 2015;22(7):711–725. doi:10.1128/CVI.00763-1425924765
   PubMedGoogle Scholar
• Morrison C. Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015;14(11):737–738. doi:10.1038/nrd477026514853
   PubMed Web of Science ®Google Scholar
• Qiu H, Cassan R, Johnstone D, et al. Novel Clostridium difficile anti-toxin (TcdA and TcdB) humanized monoclonal antibodies demonstrate In Vitro neutralization across a broad spectrum of clinical strains and In Vivo potency in a hamster spore challenge model. PLoS One. 2016;11(6):e0157970. doi:10.1371/journal.pone.015797027336843
   PubMed Web of Science ®Google Scholar
• Davies NL, Compson JE, Mackenzie B, et al. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clin Vaccine Immunol. 2013;20(3):377–390. doi:10.1128/CVI.00625-1223324518
   PubMedGoogle Scholar
• Marozsan AJ, Ma D, Nagashima KA, et al. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis. 2012;206(5):706–713. doi:10.1093/infdis/jis41622732923
   PubMed Web of Science ®Google Scholar
• Hernandez LD, Kroh HK, Hsieh E, et al. Epitopes and mechanism of action of the Clostridium difficile toxin A-neutralizing antibody actoxumab. J Mol Biol. 2017;429(7):1030–1044. doi:10.1016/j.jmb.2017.02.01028232034
   PubMed Web of Science ®Google Scholar
• Milani C, Ticinesi A, Gerritsen J, et al. Gut microbiota composition and Clostridium difficile infection in hospitalized elderly individuals: a metagenomic study. Sci Rep. 2016;6:25945. doi:10.1038/srep2594527166072
   PubMed Web of Science ®Google Scholar
• Martinez I, Lattimer JM, Hubach KL, et al. Gut microbiome composition is linked to whole grain-induced immunological improvements. ISME J. 2013;7(2):269–280. doi:10.1038/ismej.2012.10423038174
   PubMed Web of Science ®Google Scholar
• Dzunkova M, D’Auria G, Xu H, et al. The monoclonal antitoxin antibodies (Actoxumab-Bezlotoxumab) treatment facilitates normalization of the gut microbiota of mice with Clostridium difficile infection. Front Cell Infect Microbiol. 2016;6:119. doi:10.3389/fcimb.2016.0011927757389
   PubMed Web of Science ®Google Scholar
• Ritter AS, Petri WA Jr. New developments in chemotherapeutic options for Clostridium difficile colitis. Curr Opin Infect Dis. 2013;26(5):461–470. doi:10.1097/QCO.0b013e328363456e23982237
   PubMed Web of Science ®Google Scholar
• Hussack G, Arbabi-Ghahroudi M, Mackenzie CR, Tanha J. Isolation and characterization of Clostridium difficile toxin-specific single-domain antibodies. Methods Mol Biol. 2012;911:211–239.22886255
   PubMedGoogle Scholar
• Hussack G, Arbabi-Ghahroudi M, van Faassen H, et al. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem. 2011;286(11):8961–8976. doi:10.1074/jbc.M110.19875421216961
   PubMed Web of Science ®Google Scholar
• Andersen KK, Strokappe NM, Hultberg A, et al. Neutralization of Clostridium difficile toxin B mediated by engineered Lactobacilli that produce single-domain antibodies. Infect Immun. 2016;84(2):395–406. doi:10.1128/IAI.00870-1526573738
   PubMed Web of Science ®Google Scholar
• Shkoporov AN, Khokhlova EV, Savochkin KA, Kafarskaia LI, Efimov BA. Production of biologically active scFv and VHH antibody fragments in Bifidobacterium longum. FEMS Microbiol Lett. 2015;362(12):fnv083. doi:10.1093/femsle/fnv08325994292
   PubMed Web of Science ®Google Scholar
• Unger M, Eichhoff AM, Schumacher L, et al. Selection of nanobodies that block the enzymatic and cytotoxic activities of the binary Clostridium difficile toxin CDT. Sci Rep. 2015;5:7850. doi:10.1038/srep0785025597743
   PubMed Web of Science ®Google Scholar
• Hong HA, Hitri K, Hosseini S, et al. Mucosal antibodies to the C terminus of toxin A prevent colonization of Clostridium difficile. Infect Immun. 2017;85(4):e01060-16. doi:10.1128/IAI.01060-16.
   Web of Science ®Google Scholar
• Sulea T, Hussack G, Ryan S, Tanha J, Purisima EO. Application of Assisted Design of Antibody and Protein Therapeutics (ADAPT) improves efficacy of a Clostridium difficile toxin A single-domain antibody. Sci Rep. 2018;8(1):2260. doi:10.1038/s41598-018-20599-429396522
   PubMed Web of Science ®Google Scholar
• Lyerly DM, Phelps CJ, Toth J, Wilkins TD. Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun. 1986;54(1):70–76.2428753
   PubMed Web of Science ®Google Scholar
• Roberts A, McGlashan J, Al-Abdulla I, et al. Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection. Infect Immun. 2012;80(2):875–882. doi:10.1128/IAI.05684-1122144483
   PubMed Web of Science ®Google Scholar
• van Dissel JT, de Groot N, Hensgens CM, et al. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol. 2005;54(Pt 2):197–205. doi:10.1099/jmm.0.45773-015673517
   PubMed Web of Science ®Google Scholar
• Numan SC, Veldkamp P, Kuijper EJ, van Den Berg RJ, van Dissel JT. Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut. 2007;56(6):888–889. doi:10.1136/gut.2006.11901617519495
   PubMed Web of Science ®Google Scholar
• Mattila E, Anttila VJ, Broas M, et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis. 2008;40(9):702–708. doi:10.1080/0036554080196496019086244
   PubMed Web of Science ®Google Scholar
• Hutton ML, Cunningham BA, Mackin KE, et al. Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative. Sci Rep. 2017;7(1):3665. doi:10.1038/s41598-017-03982-528623367
   PubMed Web of Science ®Google Scholar
• O’Brien JB, McCabe MS, Athie-Morales V, McDonald GS, Ni Eidhin DB, Kelleher DP. Passive immunisation of hamsters against Clostridium difficile infection using antibodies to surface layer proteins. FEMS Microbiol Lett. 2005;246(2):199–205. doi:10.1016/j.femsle.2005.04.00515899406
   PubMed Web of Science ®Google Scholar
• Ghose C, Eugenis I, Sun X, et al. Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC. Emerg Microbes Infect. 2016;5:e8. doi:10.1038/emi.2016.826839147
   PubMed Web of Science ®Google Scholar
• Bojanova DP, Bordenstein SR. Fecal transplants: what is being transferred? PLoS Biol. 2016;14(7):e1002503. doi:10.1371/journal.pbio.100250327404502
   PubMed Web of Science ®Google Scholar
• Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol. 2007;3(9):541–548. doi:10.1038/nchembio.2007.2417710100
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–498; quiz 499. doi:10.1038/ajg.2013.4
   Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–415. doi:10.1056/NEJMoa120503723323867
   PubMed Web of Science ®Google Scholar
• Pecere S, Sabatelli M, Fantoni M, Ianiro G, Gasbarrini A, Cammarota G. Letter: faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;42(8):1030. doi:10.1111/apt.1336226374258
   PubMed Web of Science ®Google Scholar
• Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53(10):994–1002. doi:10.1093/cid/cir63222002980
   PubMed Web of Science ®Google Scholar
• Bang BW, Park JS, Kim HK, et al. Fecal microbiota transplantation for refractory and recurrent Clostridium difficile infection: a case series of nine patients. Korean J Gastroenterol. 2017;69(4):226–231. doi:10.4166/kjg.2017.69.4.22628449424
   PubMedGoogle Scholar
• Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2016;165(9):609–616. doi:10.7326/M16-027127547925
   PubMed Web of Science ®Google Scholar
• Carlucci C, Petrof EO, Allen-Vercoe E. Fecal microbiota-based therapeutics for recurrent Clostridium difficile infection, ulcerative colitis and obesity. EBioMedicine. 2016;13:37–45. doi:10.1016/j.ebiom.2016.09.02927720396
   PubMed Web of Science ®Google Scholar
• Anand R, Song Y, Garg S, et al. Effect of aging on the composition of fecal microbiota in donors for FMT and its impact on clinical outcomes. Dig Dis Sci. 2017;62(4):1002–1008. doi:10.1007/s10620-017-4449-628181098
   PubMed Web of Science ®Google Scholar
• Lagier JC, Delord M, Million M, et al. Dramatic reduction in Clostridium difficile ribotype 027-associated mortality with early fecal transplantation by the nasogastric route: a preliminary report. Eur J Clin Microbiol Infect Dis. 2015;34(8):1597–1601. doi:10.1007/s10096-015-2394-x25947205
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kato H, Fujimoto T. Successful fecal microbiota transplantation as an initial therapy for Clostridium difficile infection on an outpatient basis. Intern Med. 2016;55(8):999–1000. doi:10.2169/internalmedicine.55.570127086820
   PubMed Web of Science ®Google Scholar
• Kang DW, Adams JB, Gregory AC, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5(1):10. doi:10.1186/s40168-016-0225-728122648
   PubMed Web of Science ®Google Scholar
• Giau VV, Wu SY, Jamerlan A, An SSA, Kim SY, Hulme J. Gut microbiota and their neuroinflammatory implications in Alzheimer’s disease. Nutrients. 2018;10(11):1765. doi:10.3390/nu10111765.
   Web of Science ®Google Scholar
• Baumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature. 2016;535(7610):85–93. doi:10.1038/nature1884927383983
   PubMed Web of Science ®Google Scholar
• Staley C, Kelly CR, Brandt LJ, Khoruts A, Sadowsky MJ. Complete microbiota engraftment is not essential for recovery from recurrent Clostridium difficile infection following fecal microbiota transplantation. mBio. 2016;7(6). doi:10.1128/mBio.01965-16
   PubMed Web of Science ®Google Scholar
• Julliard W, Fechner JH, Owens L, et al. Modeling the effect of the aryl hydrocarbon receptor on transplant immunity. Transplant Direct. 2017;3(5):e157. doi:10.1097/TXD.000000000000066628573192
   PubMedGoogle Scholar
• Suez J, Zmora N, Zilberman-Schapira G, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. 2018;174(6):1406–1423.e1416. doi:10.1016/j.cell.2018.08.04730193113
   PubMed Web of Science ®Google Scholar
• Lamendella R, Wright JR, Hackman J, et al. Antibiotic treatments for Clostridium difficile infection are associated with distinct bacterial and fungal community structures. mSphere. 2018;3(1). doi:10.1128/mSphere.00572-17
   Web of Science ®Google Scholar
• Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2016;14(10):1433–1438. doi:10.1016/j.cgh.2016.02.01826905904
   PubMed Web of Science ®Google Scholar
• Lamas B, Richard ML, Leducq V, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016;22(6):598–605. doi:10.1038/nm.410227158904
   PubMed Web of Science ®Google Scholar
• Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36(6):503–516. doi:10.1111/j.1365-2036.2012.05220.x22827693
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149(1):102–109.e106. doi:10.1053/j.gastro.2015.04.00125857665
   PubMed Web of Science ®Google Scholar
• Abedon ST. Phage therapy: eco-physiological pharmacology. Scientifica. 2014;2014:581639. doi:10.1155/2014/72617925031881
   PubMedGoogle Scholar
• Sybesma W, Zbinden R, Chanishvili N, et al. Bacteriophages as potential treatment for urinary tract infections. Front Microbiol. 2016;7:465. doi:10.3389/fmicb.2016.0046527148173
   PubMed Web of Science ®Google Scholar
• Khawaldeh A, Morales S, Dillon B, et al. Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. J Med Microbiol. 2011;60(Pt 11):1697–1700. doi:10.1099/jmm.0.029744-021737541
   PubMed Web of Science ®Google Scholar
• Melo LDR, Veiga P, Cerca N, et al. Development of a phage cocktail to control proteus mirabilis catheter-associated urinary tract infections. Front Microbiol. 2016;7:1024. doi:10.3389/fmicb.2016.0102427446059
   PubMed Web of Science ®Google Scholar
• Merabishvili M, Vervaet C, Pirnay JP, et al. Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization). PLoS One. 2013;8(7):e68797. doi:10.1371/journal.pone.006879723844241
   PubMed Web of Science ®Google Scholar
• Hargreaves KR, Clokie MR. Clostridium difficile phages: still difficult? Front Microbiol. 2014;5:184. doi:10.3389/fmicb.2014.0054724808893
   PubMed Web of Science ®Google Scholar
• Sullivan MJ, Petty NK, Beatson SA. Easyfig: a genome comparison visualizer. Bioinformatics. 2011;27(7):1009–1010. doi:10.1093/bioinformatics/btr03921278367
   PubMed Web of Science ®Google Scholar
• Rashid S, Barylski J, Hargreaves K, Millard A, Vinner G, Clokie M. Two novel myoviruses from the north of Iraq reveal insights into Clostridium difficile phage diversity and biology. Viruses. 2016;8(11):310. doi:10.3390/v8110310
   Web of Science ®Google Scholar
• Meessen-Pinard M, Sekulovic O, Fortier LC. Evidence of in vivo prophage induction during Clostridium difficile infection. Appl Environ Microbiol. 2012;78(21):7662–7670. doi:10.1128/AEM.02275-1222923402
   PubMed Web of Science ®Google Scholar
• Nale JY, Spencer J, Hargreaves KR, et al. Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother. 2016;60(2):968–981. doi:10.1128/AAC.01774-1526643348
   PubMed Web of Science ®Google Scholar
• Goh S, Ong PF, Song KP, Riley TV, Chang BJ. The complete genome sequence of Clostridium difficile phage phiC2 and comparisons to phiCD119 and inducible prophages of CD630. Microbiology. 2007;153(Pt 3):676–685. doi:10.1099/mic.0.2006/002436-017322187
   PubMed Web of Science ®Google Scholar
• Sebaihia M, Wren BW, Mullany P, et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet. 2006;38(7):779–786. doi:10.1038/ng183016804543
   PubMed Web of Science ®Google Scholar
• Zhang Q, Widmer G, Tzipori S. A pig model of the human gastrointestinal tract. Gut Microbes. 2013;4(3):193–200. doi:10.4161/gmic.2386723549377
   PubMed Web of Science ®Google Scholar
• Zackular JP, Moore JL, Jordan AT, et al. Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection. Nat Med. 2016;22(11):1330–1334. doi:10.1038/nm.417427668938
   PubMed Web of Science ®Google Scholar
• Seekatz AM, Young VB. Clostridium difficile and the microbiota. J Clin Invest. 2014;124(10):4182–4189. doi:10.1172/JCI7233625036699
   PubMed Web of Science ®Google Scholar
• Merril CR, Scholl D, Adhya SL. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov. 2003;2(6):489–497. doi:10.1038/nrd111112776223
   PubMed Web of Science ®Google Scholar
• Meader E, Mayer MJ, Gasson MJ, Steverding D, Carding SR, Narbad A. Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe. 2010;16(6):549–554. doi:10.1016/j.anaerobe.2010.08.00620816997
   PubMed Web of Science ®Google Scholar
• Meader E, Mayer MJ, Steverding D, Carding SR, Narbad A. Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe. 2013;22:25–30. doi:10.1016/j.anaerobe.2013.05.00123685029
   PubMed Web of Science ®Google Scholar
• Govind R, Fralick JA, Rolfe RD. In vivo lysogenization of a Clostridium difficile bacteriophage ΦCD119. Anaerobe. 2011;17(3):125–129. doi:10.1016/j.anaerobe.2011.05.01221664468
   PubMed Web of Science ®Google Scholar
• Sekulovic O, Garneau JR, Neron A, Fortier LC. Characterization of temperate phages infecting Clostridium difficile isolates of human and animal origins. Appl Environ Microbiol. 2014;80(8):2555–2563. doi:10.1128/AEM.00237-1424532062
   PubMed Web of Science ®Google Scholar
• Goh S, Hussain H, Chang BJ, Emmett W, Riley TV, Mullany P. Phage ϕC2 mediates transduction of Tn6215, encoding erythromycin resistance, between Clostridium difficile strains. mBio. 2013;4(6). doi:10.1128/mBio.00840-13
   Web of Science ®Google Scholar
• Nale JY, Chutia M, Carr P, Hickenbotham PT, Clokie MR. ‘Get in Early’; Biofilm and Wax Moth (Galleria mellonella) models reveal new insights into the therapeutic potential of Clostridium difficile bacteriophages. Front Microbiol. 2016;7:1383. doi:10.3389/fmicb.2016.0138327630633
   PubMed Web of Science ®Google Scholar
• Sekulovic O, Meessen-Pinard M, Fortier LC. Prophage-stimulated toxin production in Clostridium difficile NAP1/027 lysogens. J Bacteriol. 2011;193(11):2726–2734. doi:10.1128/JB.00787-1021441508
   PubMed Web of Science ®Google Scholar
• Nagy E, Foldes J. Inactivation of metronidazole by Enterococcus faecalis. J Antimicrob Chemother. 1991;27(1):63–70. doi:10.1093/jac/27.1.63
   Web of Science ®Google Scholar
• Anonye BO. Commentary: bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Front Cell Infect Microbiol. 2018;8:104. doi:10.3389/fcimb.2018.0002629670863
   PubMed Web of Science ®Google Scholar
• Fortier LC. Bacteriophages contribute to shaping clostridioides (Clostridium) difficile species. Front Microbiol. 2018;9:2033. doi:10.3389/fmicb.2018.0203330233520
   PubMed Web of Science ®Google Scholar
• Abaev I, Foster-Frey J, Korobova O, et al. Staphylococcal phage 2638A endolysin is lytic for Staphylococcus aureus and harbors an inter-lytic-domain secondary translational start site. Appl Microbiol Biotechnol. 2013;97(8):3449–3456. doi:10.1007/s00253-012-4252-422777279
   PubMed Web of Science ®Google Scholar
• Gaeng S, Scherer S, Neve H, Loessner MJ. Gene cloning and expression and secretion of Listeria monocytogenes bacteriophage-lytic enzymes in Lactococcus lactis. Appl Environ Microbiol. 2000;66(7):2951–2958. doi:10.1128/aem.66.7.2951-2958.200010877791
   PubMed Web of Science ®Google Scholar
• Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature. 2002;418(6900):884–889.12192412
   PubMed Web of Science ®Google Scholar
• Bai J, Kim YT, Ryu S, Lee JH. Biocontrol and rapid detection of food-borne pathogens using bacteriophages and endolysins. Front Microbiol. 2016;7:474. doi:10.3389/fmicb.2016.0047427092128
   PubMed Web of Science ®Google Scholar
• Eyre DW, Walker AS, Griffiths D, et al. Clostridium difficile mixed infection and reinfection. J Clin Microbiol. 2012;50(1):142–144. doi:10.1128/JCM.05177-1122075589
   PubMed Web of Science ®Google Scholar
• He M, Miyajima F, Roberts P, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet. 2013;45(1):109–113. doi:10.1038/ng.247823222960
   PubMed Web of Science ®Google Scholar
• Ajuebor J, McAuliffe O, O’Mahony J, Ross RP, Hill C, Coffey A. Bacteriophage endolysins and their applications. Sci Prog. 2016;99(2):183–199. doi:10.3184/003685016X1462791363770528742472
   PubMed Web of Science ®Google Scholar
• Thanissery R, Zeng D, Doyle RG, Theriot CM. A small molecule-screening pipeline to evaluate the therapeutic potential of 2-aminoimidazole molecules against Clostridium difficile. Front Microbiol. 2018;9:1206. doi:10.3389/fmicb.2018.0120629928268
   PubMed Web of Science ®Google Scholar
• Letourneau JJ, Stroke IL, Hilbert DW, et al. Synthesis and SAR studies of novel benzodiazepinedione-based inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB). Bioorg Med Chem Lett. 2018;28(23-24):3601–3605. doi: 10.1016/j.bmcl.2018.10.047.
   Web of Science ®Google Scholar
• Letourneau JJ, Stroke IL, Hilbert DW, et al. Identification and initial optimization of inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB). Bioorg Med Chem Lett. 2018;28(4):756–761. doi:10.1016/j.bmcl.2018.01.00529331267
   PubMed Web of Science ®Google Scholar
• Mayer MJ, Narbad A, Gasson MJ. Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. J Bacteriol. 2008;190(20):6734–6740. doi:10.1128/JB.00686-0818708505
   PubMed Web of Science ®Google Scholar
• Beilhartz GL, Tam J, Zhang Z, Melnyk RA. Comment on “A small-molecule antivirulence agent for treating Clostridium difficile infection”. Sci Transl Med. 2016;8(370):370tc372. doi:10.1126/scitranslmed.aaf0746
   Web of Science ®Google Scholar
• Xie Y, Tan Y, Zheng Y, Du X, Liu Q. Ebselen ameliorates beta-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer’s disease mice. J Biol Inorg Chem. 2017;22(6):851–865. doi:10.1007/s00775-017-1463-228502066
   PubMed Web of Science ®Google Scholar
• Ivarsson ME, Durantie E, Huberli C, et al. Small-molecule allosteric triggers of Clostridium difficile toxin B auto-proteolysis as a therapeutic strategy. Cell Chem Biol. 2018;26(1):17–26.e13.
   Web of Science ®Google Scholar
• Egan K, Field D, Ross RP, Cotter PD, Hill C. In silico prediction and exploration of potential bacteriocin gene clusters within the bacterial genus geobacillus. Front Microbiol. 2018;9:2116. doi:10.3389/fmicb.2018.0211630298056
   PubMed Web of Science ®Google Scholar
• Le Lay C, Dridi L, Bergeron MG, Ouellette M, Fliss IL. Nisin is an effective inhibitor of Clostridium difficile vegetative cells and spore germination. J Med Microbiol. 2016;65(2):169–175. doi:10.1099/jmm.0.00020226555543
   PubMed Web of Science ®Google Scholar
• Khosa S, Lagedroste M, Smits SH. Protein defense systems against the lantibiotic nisin: function of the immunity protein nisi and the resistance protein NSR. Front Microbiol. 2016;7:504. doi:10.3389/fmicb.2016.0050427148193
   PubMed Web of Science ®Google Scholar
• Chai C, Lee KS, Imm GS, Kim YS, Oh SW. Inactivation of Clostridium difficile spore outgrowth by synergistic effects of nisin and lysozyme. Can J Microbiol. 2017;63(7):638–643. doi:10.1139/cjm-2016-055028346844
   PubMed Web of Science ®Google Scholar
• Rea MC, O’Sullivan O, Shanahan F, et al. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol. 2012;50(3):867–875. doi:10.1128/JCM.05176-1122162545
   PubMed Web of Science ®Google Scholar
• Mathur H, Field D, Rea MC, Cotter PD, Hill C, Ross RP. Bacteriocin-antimicrobial synergy: a medical and food perspective. Front Microbiol. 2017;8:1205. doi:10.3389/fmicb.2017.0120528706513
   PubMed Web of Science ®Google Scholar
• Hanchi H, Hammami R, Gingras H, et al. Inhibition of MRSA and of Clostridium difficile by durancin 61A: synergy with bacteriocins and antibiotics. Future Microbiol. 2017;12:205–212. doi:10.2217/fmb-2016-011328262046
   PubMed Web of Science ®Google Scholar
• Rea MC, Sit CS, Clayton E, et al. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci. 2010;107(20):9352–9357. doi:10.1073/pnas.091355410720435915
   PubMed Web of Science ®Google Scholar
• Li C, Teng P, Peng Z, Sang P, Sun X, Cai J. Bis-cyclic guanidines as a novel class of compounds potent against Clostridium difficile. ChemMedChem. 2018;13(14):1414–1420. doi:10.1002/cmdc.20180024029768720
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Granata G, Cataldo MA. Novel antimicrobials for the treatment of Clostridium difficile infection. Front Med. 2018;5:96. doi:10.3389/fmed.2018.00096
   PubMed Web of Science ®Google Scholar
• Tyrrell KL, Citron DM, Merriam CV, Leoncio E, Goldstein EJC. In vitro activity of DS-2969b and comparator antimicrobial agents against Clostridioides (Clostridium) difficile, methicillin-resistant Staphylococcus aureus, and other anaerobic bacteria. Anaerobe. 2018;54:39–41. doi:10.1016/j.anaerobe.2018.04.01030096588
   PubMed Web of Science ®Google Scholar
• Van Giau V, An SSA, Hulme J. Recent advances in the treatment of pathogenic infections using antibiotics and nano-drug delivery vehicles. Drug Des Devel Ther. 2019;13:327–343. doi:10.2147/DDDT.S190577
   PubMed Web of Science ®Google Scholar
• Millan B, Park H, Hotte N, et al. Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. Clin Infect Dis. 2016;62(12):1479–1486. doi:10.1093/cid/ciw18527025836
   PubMed Web of Science ®Google Scholar